Biological therapies should be considered in patients with high disease activity despite nonsteroid antiinflammatory drug treatment. The first option among biological therapies is anti-Tumor Necrosis Factor (anti-TNF) drugs. In recent years, anti-TNF treatments have shown that clinical and ultrasonographic enthesitis may improve as well as disease activity, quality of life and acute phase reactants. In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
31
TNF inhibitors are widely used in patients with spondyloarthritis
change from ultrasonographic entesitis score at 3 months
Madrid Sonographic Enthesitis Index was used to screen etheseal sites
Time frame: before and 3 months after anti-TNF treatment
Change from disease activity
Bath Ankylosing Spondylitis Disease Activity Index was used
Time frame: before and 3 months after anti-TNF treatment
Change from disease activity
Ankylosing Spondylitis Disease Activity Score was used
Time frame: before and 3 months after anti-TNF treatment
Change from quality of life
Ankylosing Spondylitis Quality of Life was used
Time frame: before and 3 months after anti-TNF treatment
Change from Functionality
Bath Ankylosing Spondylitis Functionality Index was used
Time frame: before and 3 months after anti-TNF treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.